Premium
2′ and 3′ Ribonucleoside monophosphate in leukocytes of acute myeloid leukemia: Markers for early diagnosis of relapse
Author(s) -
Scavennec JoëLle,
Cailla Hélène,
Gastaut JeanAlbert,
Maraninchi Dominique,
Carcassonne Yves
Publication year - 1982
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910290305
Subject(s) - ribonucleoside , bone marrow , myeloid leukemia , purine , medicine , myeloid , gastroenterology , leukemia , lymphoblastic leukemia , complete remission , pyrimidine , acute leukemia , high performance liquid chromatography , chemotherapy , immunology , biology , chemistry , biochemistry , chromatography , rna , gene , enzyme
Levels of 2′ and 3′ purine and pyrimidine ribonucleoside monophosphates (2′‐, 3′‐NMP) in leukocytes from blood and/or bone marrow were measured in three adult patients with acute non‐lymphoblastic leukemias. The measurements of 2′‐, 3′‐NMP were made by high‐performance liquid chromatography (HPLC) at various times in the course of the disease. Complete remission (CR) was obtained for all three patients but two of these have since died after relapsing at 8 and 9 months, respectively. The third patient remains in CR at 1½ year. The levels of 2′‐, 3′‐NMP in the leukocytes of the patient remaining in remission have not changed since the beginning of his remission. However, in the patients who relapsed 2′‐ and 3′‐NMP levels increased first in bone marrow then in blood leukocytes. These increases occured about 3 months before the relapse was detected by morphological criteria. These data suggest that 2′‐, 3′‐NMP measurements may have a prognostic value if used to monitor patients with acute myeloid leukemia in CR.